Comparative Acute Systemic Toxicity of Several Quinoxaline 1,4-Di-N-oxides in Wistar Rats
暂无分享,去创建一个
A. Azqueta | A. García-Rodríguez | A. Monge | A. Gil | B. Zarranz | J. A. García-Jalón | F. Cia | Adela de-Cerain | J. García-Jalón | Belén Zarranz
[1] H. G. Vogel. Guidelines for the Care and Use of Laboratory Animals , 2007 .
[2] I. White,et al. Acute lesions in rats caused by 3-amino-1,2,4-benzotriazine-1,4-dioxide (SR 4233) or nitromin: a comparison with rates of reduction in microsomal systems from target organs , 2006, Archives of Toxicology.
[3] P. Corona,et al. Quinoxaline 1,4-dioxide: a versatile scaffold endowed with manifold activities. , 2005, Current medicinal chemistry.
[4] A. Costa-Filho,et al. Novel Cu(II) quinoxaline N1,N4-dioxide complexes as selective hypoxic cytotoxins. , 2005, European journal of medicinal chemistry.
[5] S. Cannas,et al. In vitro activity of new quinoxalin 1,4-dioxide derivatives against strains of Mycobacterium tuberculosis and other mycobacteria. , 2005, International journal of antimicrobial agents.
[6] H. Cerecetto,et al. Quinoxaline N,N'-dioxide derivatives and related compounds as growth inhibitors of Trypanosoma cruzi. Structure-activity relationships. , 2004, Bioorganic & medicinal chemistry letters.
[7] H. Gali-Muhtasib,et al. Quinoxaline 1,4-dioxides are novel angiogenesis inhibitors that potentiate antitumor effects of ionizing radiation. , 2004, International journal of oncology.
[8] S. Zanetti,et al. Synthesis, anti-mycobacterial, anti-trichomonas and anti-candida in vitro activities of 2-substituted-6,7-difluoro-3-methylquinoxaline 1,4-dioxides. , 2004, European journal of medicinal chemistry.
[9] S. Irwin,et al. Comprehensive observational assessment: Ia. A systematic, quantitative procedure for assessing the behavioral and physiologic state of the mouse , 1968, Psychopharmacologia.
[10] E. Essassi,et al. [Synthesis and pharmacological study of three 1-alkyl-3-(ethoxycarbonylmethylene)-2-oxo quinoxalines]. , 2002, Annales Pharmaceutiques Françaises.
[11] S. Zanetti,et al. Novel substituted quinoxaline 1,4-dioxides with in vitro antimycobacterial and anticandida activity. , 2002, European journal of medicinal chemistry.
[12] H. Gali-Muhtasib,et al. Quinoxaline 1,4‐dioxides: Hypoxia‐selective therapeutic agents , 2002, Molecular carcinogenesis.
[13] A. Monge,et al. Anti-Mycobacterium tuberculosis Agents Derived from Quinoxaline-2-carbonitrile and Quinoxaline-2-carbonitrile 1,4-di-N-oxide , 2002, Arzneimittelforschung.
[14] H. Gali-Muhtasib,et al. Quinoxaline 1,4-dioxides as anticancer and hypoxia-selective drugs. , 2001, Oncology reports.
[15] A. López de Cerain,et al. New quinoxalinecarbonitrile 1,4-di-N-oxide derivatives as hypoxic-cytotoxic agents. , 2000, European journal of medicinal chemistry.
[16] B. Wouters,et al. Cisplatin anti-tumour potentiation by tirapazamine results from a hypoxia-dependent cellular sensitization to cisplatin , 1999, British Journal of Cancer.
[17] A. López de Cerain,et al. Synthesis and antituberculosis activity of new 2-quinoxalinecarbonitrile 1,4-di-N-oxides. , 1999, Die Pharmazie.
[18] A. López de Cerain,et al. New Quinoxaline 1,4-Di-N-oxides for Treatment of Tuberculosis , 1999, Arzneimittelforschung.
[19] N. Sodir,et al. Photoprotective effects of some quinoxaline 1,4-dioxides in hairless mice , 1998, Medical oncology.
[20] A. López de Cerain,et al. Synthesis and antituberculosis activity of some new 2-quinoxalinecarbonitriles. , 1998, Farmaco.
[21] A. López de Cerain,et al. Hypoxia-selective agents derived from 2-quinoxalinecarbonitrile 1,4-di-N-oxides. 2. , 1995, Journal of medicinal chemistry.
[22] E. Clarke,et al. Hypoxia-selective agents derived from quinoxaline 1,4-di-N-oxides. , 1995, Journal of medicinal chemistry.
[23] M. Naylor. Novel N-oxides as bioreductive drugs. , 1994, Oncology Research.
[24] M. Haddadin,et al. The Beirut Reaction , 1993 .
[25] S. Zanetti,et al. 2-Phenyl-6(7)-R-substituted quinoxalines N-oxides. Synthesis, structure elucidation and antimicrobial activity , 1990 .
[26] M. Lemmon,et al. Structure-activity relationships for benzotriazine di-N-oxides. , 1989, International journal of radiation oncology, biology, physics.
[27] L. Chappel,et al. Pyridoquinoxaline N-oxides. 1. A new class of antitrichomonal agents. , 1982, Journal of medicinal chemistry.
[28] B. Dominy,et al. Synthesis and antibacterial activity of 1-hydroxy-1-methyl-1,3-dihydrofuro[3,4-b]quinoxaline 4,9-dioxide and related compounds. , 1979, Journal of medicinal chemistry.
[29] J. Dirlam,et al. Synthesis and antibacterial activity of isomeric 6- and 7-acetyl-3-methyl-2- quinoxalinecarbozamide 1,4-dioxides. , 1978, Journal of medicinal chemistry.
[30] W. Suter,et al. Mode of Action of Quindoxin and Substituted Quinoxaline-di-N-Oxides on Escherichia coli , 1978, Antimicrobial Agents and Chemotherapy.
[31] C. O. Knowles. Chemistry and toxicology of quinoxaline, organotin, organofluorine, and formamidine acaricides. , 1976, Environmental health perspectives.
[32] G. Sponer,et al. Acute toxicity of various solvents in the mouse and rat. LD50 of ethanol, diethylacetamide, dimethylformamide, dimethylsulfoxide, glycerine, N-methylpyrrolidone, polyethylene glycol 400, 1,2-propanediol and Tween 20. , 1976, Arzneimittel-Forschung.